Recombinant ASF Live Attenuated Virus Strains as Experimental Vaccine Candidates.

Abstract

African swine fever (ASF) is causing a pandemic affecting swine in a large geographical area of the Eastern Hemisphere, from Central Europe to East and Southeast Asia, and recently in the Americas, the Dominican Republic and Haiti. The etiological agent, ASF virus (ASFV), infects both domestic and wild swine and produces a variety of clinical presentations depending on the virus strain and the genetics of the pigs infected. No commercial vaccines are currently available, although experimental recombinant live attenuated vaccine candidates have been shown to be efficacious in protecting animals against disease when challenged with homologous virulent strains. This review attempts to systematically provide an overview of all the live attenuated strains that have been shown to be experimental vaccine candidates. Moreover, it aims to analyze the development of these vaccine candidates, obtained by deleting specific genes or group of genes, and their efficacy in preventing virus infection and clinical disease after being challenged with virulent isolates. This report summarizes all the experimental vaccine strains that have shown promise against the contemporary pandemic strain of African swine fever.

• Authors: Douglas P Gladue, Manuel V Borca
• Journal: Viruses (Viruses) Vol. 14 Issue 5 (04 23 2022) ISSN: 1999-4915 [Electronic] Switzerland
• PMID: 35632620 (Publication Type: Journal Article, Review)

Chemical References

• Vaccines, Attenuated
• Vaccines, Synthetic
• Viral Vaccines

Topics

• African Swine Fever
• African Swine Fever Virus (genetics)
• Animals
• Swine
• Vaccines, Attenuated (genetics)
• Vaccines, Synthetic (genetics)
• Viral Vaccines (genetics)
• Viruses, Unclassified